CIK 0001882782 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Odyssey Therapeutics, Inc.
Sign in to watch- Ticker
- ODTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863384382
- Phone
- (212) 841-1000
- Business address
- 51 SLEEPER STREET, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-11 | Opipari Anthony W. See Remarks | Conversion · Series B Convertible Preferred Stock | −11,083 | 0 | ||
| 2026-05-11 | Opipari Anthony W. See Remarks | Conversion · Series C Convertible Preferred Stock | −20,000 | 0 | ||
| 2026-05-11 | Opipari Anthony W. See Remarks | Conversion · Series D Convertible Preferred Stock | −17,545 | 0 | ||
| 2026-05-11 | Opipari Anthony W. See Remarks | Option exercise · Series D Warrants (Right to Buy) | −5,263 | 0 | ||
| 2026-05-08 | Dimension Capital II, L.P. Director | Conversion | +1,709,543 | 2,222,405 | ||
| 2026-05-08 | Dimension Capital II, L.P. Director | Purchase | +1,111,111 | $18.00 | $20.0M | 3,333,516 |
| 2026-05-08 | Dimension Capital II, L.P. Director | Conversion · Series D Convertible Preferred Stock | −16,611,626 | 0 | ||
| 2026-05-08 | LEIDEN JEFFREY M Director | Purchase | +5,000 | $20.00 | $100K | 270,198 |
| 2026-05-08 | Haas Jason Chief Financial Officer | Purchase | +1,000 | $20.00 | $20K | 62,908 |
| 2026-05-07 | LEIDEN JEFFREY M Director | Grant or award · Stock Option (Right to Buy) | +626,220 | 626,220 | ||
| 2026-05-07 | SMITH IAN F Director | Grant or award · Stock Option (Right to Buy) | +27,393 | 27,393 | ||
| 2026-05-07 | Odegard Valerie Director | Grant or award · Stock Option (Right to Buy) | +27,393 | 27,393 | ||
| 2026-05-07 | Tatsis Ourania Director | Grant or award · Stock Option (Right to Buy) | +27,393 | 27,393 | ||
| 2026-05-07 | Dales Natalie See Remarks | Grant or award · Stock Option (Right to Buy) | +79,773 | 79,773 | ||
| 2026-05-07 | Walbert Timothy P Director | Grant or award · Stock Option (Right to Buy) | +27,393 | 27,393 | ||
| 2026-05-07 | Glick Gary D See Remarks | Grant or award · Stock Option (Right to Buy) | +884,450 | 884,450 | ||
| 2026-05-07 | Opipari Anthony W. See Remarks | Grant or award · Stock Option (Right to Buy) | +250,203 | 250,203 | ||
| 2026-05-07 | Opipari Anthony W. See Remarks | Grant or award · Stock Option (Right to Buy) | +27,777 | 27,777 | ||
| 2026-05-07 | Todd Collin M See Remarks | Grant or award · Stock Option (Right to Buy) | +93,904 | 93,904 |
Page 4 of 4 · 79 trades